|
|
Article: Gloucester Pharmaceuticals Reports on Preclinical Study of Depsipeptide in Pancreatic Cancer from the 97th Annual Meeting of The American Association of Cancer Research.
- Article from:
- Business Wire
- Article date:
- April 5, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Significant Preclinical Activity Seen for Depsipeptide in Combination with Gemcitabine
Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced the presentation of preclinical research suggesting the potential of the Company's lead product candidate, depsipeptide (FK228), in combination with gemcitabine, as a treatment for pancreatic adenocarcinoma. The findings were reported at the 97th Annual Meeting of the American Association of Cancer Research (AACR), taking place in Washington, DC. Full text of the abstract #3829 "In Vivo Evaluation of Depsipeptide (FK228) Alone or in Combination with ...